In the first of 3 videos, Paul Lammers, MD, MSc, chief executive officer of Triumvira, discusses the company’s unique T antigen coupler (TAC) T-cell technology. Daniel Olson, MD, Assistant Professor of Medicine, the University of Chicago Medicine, presented an abstract about the ongoing phase 1/2 study evaluating the safety and efficacy of TAC01 in HER2-expressing relapsed or refractory tumors (NCT04727151) at the Society for Immunotherapy of Cancer 38th Annual Meeting November 1-5, 2023
Here, Lammers describes the TAC mechanisms and what sets it apart from chimeric antigen receptor (CAR) T-cell therapy.
Related: About the Phase 1/2 Trial of TAC-01 in HER2-Expressing Solid Tumors
